Delmar Pharmaceuticals Inc., of Vancouver, British Columbia, updated the terms of its previously announced rights offering. The subscription period for the rights offering will now expire on June 25. Unit pricing remains $1,000 per unit of series C convertible preferred stock and warrants to purchase Delmar's common stock. But each unit will now consist of 209 warrants to purchase the company's common stock at an adjusted exercise price of $3.10 per share.